Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment

被引：26

作者：

Lachowiez, Curtis A. ^{[1
]}

Reville, Patrick K. ^{[1
]}

Kantarjian, Hagop ^{[2
]}

Jabbour, Elias ^{[2
]}

Borthakur, Gautam ^{[2
]}

Daver, Naval ^{[2
]}

Issa, Ghayas ^{[2
]}

Furudate, Ken ^{[3
]}

Tanaka, Tomoyuki ^{[3
]}

Pierce, Sherry ^{[2
]}

Tang, Guilin ^{[4
]}

Patel, Keyur P.

Medeiros, Jeffrey

Abbas, Hussein A. ^{[2
]}

Haddad, Fadi ^{[2
]}

Hammond, Daniel ^{[2
]}

Short, Nicholas J. ^{[2
]}

Maiti, Abhishek ^{[2
]}

Yilmaz, Musa ^{[2
]}

Sasaki, Koji ^{[2
]}

Takahashi, Koichi ^{[2
]}

Pemmaraju, Naveen ^{[2
]}

Konopleva, Marina ^{[2
]}

Garcia-Manero, Guillermo ^{[2
]}

Ravandi, Farhad ^{[2
]}

Kadia, Tapan M. ^{[2
]}

Loghavi, Sanam ^{[4
]}

DiNardo, Courtney D. ^{[2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept hematopathol, Houston, TX 77030 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2022年 / 97卷 / 11期

关键词：

PROGNOSTIC-SIGNIFICANCE; AML; RECOMMENDATIONS; AZACITIDINE; DIAGNOSIS;

D O I：

10.1002/ajh.26694

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) mutations occur frequently in newly diagnosed (ND) acute myeloid leukemia (AML) often with co-occurring NPM1 mutations, which may influence treatment outcomes. Detailed analysis of IDH-mutated AML treated with venetoclax and influence of co-occurring NPM1 mutations remains unclear. This retrospective single-center cohort study evaluated clinical and molecular demographics,response and survival, and impact of co-occurring NPM1 mutations in patients with IDH1 or IDH2-mutated AML. 556 patients with IDH1, IDH2, and/or NPM1 mutated AML were included. Patients with IDH1(mut) AML (N = 119) were more likely to have older age, sAML, ELN-adverse risk disease, and adverse-risk cytogenetics compared to those with IDH2(mut) (N = 229) or IDHwt/NPM1(mut) AML (N = 208). In multivariate analysis, patients with IDH2(mut) (HR 0.61 [95%CI: 0.43-0.88], p value: .007) or IDHwt/NPM1(mut) (HR 0.65 [95% CI: 0.45-0.94], p value: .024) AML had a decreased risk of death versus IDH1(mut) AML. Venetoclax-based lower-intensity regimens partially abrogated the detrimental effect of IDH1(mut) with similar OS observed between IDH1(mut)/NPM1(wt), IDH2(mut)/NPM1(wt), and IDHwt/NPM1(mut) AML. With regards to the influence of IDHmut/NPM1(mut) cases, IC improved survival in IDH2(mut)/NPM1(mut) versus IDH2(mut)/NPM1(wt) AML (HR: 0.54 [95% CI: 0.2644-1.082], p value: .077), while venetoclax-based therapy improved survival in IDH1(mut)/NPM1(mut) versus IDH1(mut)/NPM1(wt) AML (HR: 0.094 [95% CI: 0.01-0.74], p value: .0056). Differing outcomes were observed in IDH1(mut) versus IDH2(mut) or NPM1(mut) AML which were influenced by co-occurring NPM1 mutations and partially abrogated with venetoclax-based therapy. Given the differing biology and survival in IDH1(mut) AML, investigations incorporating molecularly targeted therapies such as IDH inhibitors remain warranted in this subgroup.

引用

页码：1443 / 1452

页数：10

共 44 条

[21] Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML [J].

Hollink, I. H. I. M. ;

Zwaan, C. M. ;

Zimmermann, M. ;

Arentsen-Peters, T. C. J. M. ;

Pieters, R. ;

Cloos, J. ;

Kaspers, G. J. L. ;

de Graaf, S. S. N. ;

Harbott, J. ;

Creutzig, U. ;

Reinhardt, D. ;

van den Heuvel-Eibrink, M. M. ;

Thiede, C. .

LEUKEMIA, 2009, 23 (02) :262-270

[22] Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML [J].

I H I M Hollink ;

C M Zwaan ;

M Zimmermann ;

T C J M Arentsen-Peters ;

R Pieters ;

J Cloos ;

G J L Kaspers ;

S S N de Graaf ;

J Harbott ;

U Creutzig ;

D Reinhardt ;

M M van den Heuvel-Eibrink ;

C Thiede .

Leukemia, 2009, 23 :262-270

[23] Outcomes of Older Patients with NPM1 Mutated and FLT3-ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation [J].

Jentzsch, Madlen ;

Grimm, Juliane ;

Bill, Marius ;

Goldmann, Karoline ;

Schulz, Julia ;

Niederwieser, Dietger ;

Platzbecker, Uwe ;

Schwind, Sebastian .

HEMASPHERE, 2020, 4 (01)

[24] Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors [J].

Bewersdorf, Jan Philipp ;

Shallis, Rory M. ;

Derkach, Andriy ;

Goldberg, Aaron D. ;

Stein, Anthony ;

Stein, Eytan M. ;

Marcucci, Guido ;

Zeidan, Amer M. ;

Shimony, Shai ;

DeAngelo, Daniel J. ;

Stone, Richard M. ;

Aldoss, Ibrahim ;

Ball, Brian J. ;

Stahl, Maximilian .

LEUKEMIA & LYMPHOMA, 2023, 64 (01) :188-196

[25] Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy [J].

Weng, Guangyang ;

Huang, Jingya ;

An, Na ;

Zhang, Yu ;

Yu, Guopan ;

Sun, Zhiqiang ;

Lin, Dongjun ;

Deng, Lan ;

Liang, Xinquan ;

Xiao, Jie ;

Zhang, Hongyu ;

Guo, Ziwen ;

He, Xin ;

Jin, Hua ;

Liu, Qifa ;

Du, Xin .

CANCER MEDICINE, 2024, 13 (02)

[26] Integrin expression and adhesivity to fibronectin in primary acute myeloid leukemia cells: Impact of NPM1 and FLT3 mutations [J].

Kuzelova, Katerina ;

Obr, Adam ;

Markova, Jana ;

Gasova, Zdenka .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105 (05) :578-587

[27] Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations [J].

Freeman, Sylvie D. ;

Hills, Robert K. ;

Virgo, Paul ;

Khan, Naeem ;

Couzens, Steve ;

Dillon, Richard ;

Gilkes, Amanda ;

Upton, Laura ;

Nielsen, Ove Juul ;

Cavenagh, James D. ;

Jones, Gail ;

Khwaja, Asim ;

Cahalin, Paul ;

Thomas, Ian ;

Grimwade, David ;

Burnett, Alan K. ;

Russell, Nigel H. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15) :1486-+

[28] Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens [J].

Baden, David ;

Zukunft, Sven ;

Hernandez, Gema ;

Wolgast, Nadine ;

Steinhaeuser, Sophie ;

Pohlmann, Alexander ;

Schliemann, Christoph ;

Mikesch, Jan-Henrik ;

Steffen, Bjoern ;

Sauer, Tim ;

Hanoun, Maher ;

Schaefer-Eckart, Kerstin ;

Krause, Stefan W. ;

Haenel, Mathias ;

Einsele, Hermann ;

Jost, Edgar ;

Bruemmendorf, Tim H. ;

Scholl, Sebastian ;

Hochhaus, Andreas ;

Neubauer, Andreas ;

Burchert, Andreas ;

Kaufmann, Martin ;

Niemann, Dirk ;

Schaich, Markus ;

Blau, Wolfgang ;

Kiani, Alexander ;

Goerner, Martin ;

Kaiser, Ulrich ;

Kullmer, Johannes ;

Weber, Thomas ;

Berdel, Wolfgang E. ;

Ehninger, Gerhard ;

Mueller-Tidow, Carsten ;

Platzbecker, Uwe ;

Serve, Hubert ;

Bornhaeuser, Martin ;

Roellig, Christoph ;

Baldus, Claudia D. ;

Fransecky, Lars .

HAEMATOLOGICA, 2024, 109 (08) :2469-2477

[29] IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication [J].

Paschka, Peter ;

Schlenk, Richard F. ;

Gaidzik, Verena I. ;

Habdank, Marianne ;

Kroenke, Jan ;

Bullinger, Lars ;

Spaeth, Daniela ;

Kayser, Sabine ;

Zucknick, Manuela ;

Goetze, Katharina ;

Horst, Heinz-A. ;

Germing, Ulrich ;

Doehner, Hartmut ;

Doehner, Konstanze .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) :3636-3643

[30] Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF [J].

Jimenez-Vicente, Carlos ;

Martinez-Roca, Alexandra ;

Pomares, Helena ;

Castano-Diez, Sandra ;

Guijarro, Francesca ;

Lopez-Guerra, Monica ;

Bataller, Alex ;

Esteban, Daniel ;

Cortes-Bullich, Albert ;

Perez-Valencia, Amanda Isabel ;

Guardia-Torrelles, Ares ;

Zugasti, Ines ;

Rovira, Montserrat ;

Fernandez-Aviles, Francesc ;

Colomer, Dolors ;

Arnan, Montserrat ;

Diaz-Beya, Marina ;

Esteve, Jordi .

LEUKEMIA RESEARCH, 2023, 135

← 1 2 3 4 5 →